A federal district judge has dismissed two community health centers’ federal and state antitrust claims against four insulin and diabetes drug manufacturers over the companies’ denials of 340B pricing when covered entities use contract pharmacies.
Chief Judge Elizabeth Wolford of U.S. District Court for the District of Western New York on Sept. 2 agreed with AstraZeneca, Lilly, Novo Nordisk, and Sanofi that New York state health center Mosaic Health and Virginia-based Central Virginia Health Services’ (CVHS) “failed to plausibly allege” that the four companies illegally colluded to deny 340B pricing on insulin and other diabetes medicines, in violation of federal and state laws.
A federal district judge has dismissed two community health centers’ federal and state antitrust claims against four insulin and diabetes drug manufacturers over the companies’ denials of 340B pricing when covered entities use contract pharmacies.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
